DUBLIN–(BUSINESS WIRE)–The “Global Healthcare Analytical Testing Services Market by Type (Method Development & Validation, Cell-based Assays, Stability Testing, Heavy Metal Testing, Thermal Analysis, Cleaning Validation), End-user (Pharmaceutical Companies, CROs) and Region – Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering.
The global healthcare analytical testing services market is projected to reach USD 9.8 billion by 2026 from USD 5.6 billion in 2021, at a CAGR of 11.9%.
Growth in the market is driven by the rising trend of outsourcing of analytical testing by pharmaceutical companies and medical device companies, an increasing number of clinical trials, and the rising acceptance of the QbD approach in pharma research and manufacturing.
The batch-release testing segment is expected to grow at the highest rate, by type, in the healthcare analytical testing services market, in the forecast period
On the basis of type, the healthcare analytical testing services market is segmented into bioanalytical testing, physical characterization, method development & validation, stability testing, batch-release testing, raw material testing, microbial testing, and environmental monitoring services.
In the forecast period, batch-release testing segment is expected to grow at the highest rate, by type. The high growth of this segment can be attributed to the utility of these services in ensuring that pharmaceutical products are compliant with regulations and meet specifications within the marketing authorization (MA) or Clinical Trial Dossier (CTD). Within the batch-release testing segment, the dissolution testing services segment holds the highest market share and is growing at the highest rate in the forecast period.
In the bioanalytical testing services segment, cell-based assay services holds the highest share in the market in the forecast period
On the basis of type, the healthcare analytical testing services market is segmented into bioanalytical testing, physical characterization, method development & validation, stability testing, batch-release testing, raw material testing, microbial testing, and environmental monitoring services.
The bioanalytical testing services segment holds the highest share during the forecast period. Within this segment, cell-based assay services holds the highest market share. This high market share can be attributed to the usage of cell-based assays in high-throughput screening, which has increased due to their ability to provide relevant in vivo biological information, consequently accelerating the process of drug discovery.
The medical device companies segment is expected to grow at the highest rate, by end user, in the healthcare analytical testing services market, in the forecast period
In this report, the healthcare analytical testing services market has been segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and contract research organizations (CROs), by end user. The medical device companies segment is expected to grow at the highest rate in the market in the forecast period.
The high growth rate of the segment maybe attributed to increasing demand by OEMs for more services and expertise, evolving regulatory scenarios, technological advancements in medical devices, and the adoption of point-of-care (POC) testing driving the demand for healthcare analytical testing services among medical device companies.
APAC is expected to grow at the highest rate in the healthcare analytical testing services market, by region, in the forecast period
The healthcare analytical testing services market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific region is expected to grow at the highest rate, by region, in the forecast period. This high growth rate can be attributed to significant growth opportunities in emerging Asian countries and lower their production costs by shifting manufacturing and drug R&D operations to the region, making this region a major destination for drug discovery and development. Moreover, the large number of qualified researchers and the low cost of operations in APAC countries, such as India and China, have supported this trend.
Market Dynamics
Drivers
- Focus on Analytical Testing of Biologics & Biosimilars
- Increasing Outsourcing of Analytical Testing by Pharmaceutical Companies and Medical Device Companies
- Increasing Number of Clinical Trials
- Rising Acceptance of the Quality-By-Design Approach in Pharma Research and Manufacturing
Restraints
- Shortage of Skilled Professionals
Opportunities
- Specialized Testing
- Emerging Markets
Challenges
- Specific Requirements of Innovative Formulations and Medical Devices
- Need to Improve the Sensitivity of Bioanalytical Methods
- Rising Costs of Bioanalytical Testing Methods and Technology
Companies Mentioned
- Almac Group
- ALS Life Sciences
- Anacura
- CD Biosciences
- Charles River Laboratories
- Danaher Corporation
- Element Materials Technology
- Eurofins Scientific
- Frontage Laboratories
- Icon
- Impact Analytical
- Intertek Group
- Laboratory Corporation of America Holdings
- LGC Limited (Cinven)
- Medpace Holdings
- Merck KGaA
- Pace Analytical Services
- PPD
- Sartorius AG
- SGS
- Source Bioscience
- Steris
- Syneos Health
- Thermo Fisher Scientific
- Wuxi Apptec
For more information about this report visit https://www.researchandmarkets.com/r/56mho
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900